Abstract
The treatment of bipolar disorder (BD) usually requires combination therapies, with the critical issue of the emergence of adverse drug reactions (ADRs) and the possibility of low treatment adherence. Genetic polymorphisms are hypothesized to modulate the pharmacodynamics of psychotropic drugs, representing potential biological markers of ADRs. This study investigated genes involved in the regulation of neuroplasticity (BDNF, ST8SIA2), second messenger cascades (GSK3B, MAPK1, and CREB1), circadian rhythms (RORA), transcription (SP4, ZNF804A), and monoaminergic system (HTR2A and COMT) in the risk of neurological, psychic, autonomic, and other ADRs. Two independent samples of BD patients naturalistically treated were included (COPE-BD n = 147; STEP-BD n = 659). In the COPE-BD 34 SNPs were genotyped, while in the STEP-BD polymorphisms in the selected genes were extracted from the genome-wide dataset. Each ADRs group was categorized as absent-mild or moderate-severe and logistic regression with appropriate covariates was applied to identify possible risk genotypes/alleles. 58.5 and 93.5 % of patients were treated with mood stabilizers, 44.2 and 50.7 % were treated with antipsychotics, and 69.4 and 46.1 % were treated with antidepressants in the COPE-BD and STEP-BD, respectively. Our findings suggested that ST8SIA2 may be associated with psychic ADRs, as shown in the COPE-BD (rs4777989 p = 0.0017) and STEP-BD (rs56027313, rs13379489 and rs10852173). A cluster of RORA SNPs around rs2083074 showed an effect on psychic ADRs in the STEP-BD. Trends supporting the association between HTR2A and autonomic ADRs were found in both samples. Confirmations are needed particularly for ST8SIA2 and RORA since the few available data regarding their role in relation to psychotropic ADRs.
Similar content being viewed by others
References
Al-Qudah M, Anderson CD, Mahavadi S, Bradley ZL, Akbarali HI, Murthy KS, Grider JR (2014) Brain-derived neurotrophic factor enhances cholinergic contraction of longitudinal muscle of rabbit intestine via activation of phospholipase C. Am J Physiol Gastrointest Liver Physiol 306:G328–G337
Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT (2010) Data quality control in genetic case-control association studies. Nat Protoc 5:1564–1573
Angata K, Nakayama J, Fredette B, Chong K, Ranscht B, Fukuda M (1997) Human STX polysialyltransferase forms the embryonic form of the neural cell adhesion molecule. Tissue-specific expression, neurite outgrowth, and chromosomal localization in comparison with another polysialyltransferase, PST. J Biol Chem 272:7182–7190
Baldessarini R, Henk H, Sklar A, Chang J, Leahy L (2008) Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv 59:1175–1183
Balog Z, Kiss I, Keri S (2011) ZNF804A may be associated with executive control of attention. Genes Brain Behav 10:223–227
Basile VS, Ozdemir V, Masellis M, Meltzer HY, Lieberman JA, Potkin SG, Macciardi FM, Petronis A, Kennedy JL (2001) Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry 6:230–234
Beaulieu JM, Gainetdinov RR, Caron MG (2009) Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49:327–347
Black AR, Black JD, Azizkhan-Clifford J (2001) Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 188:143–160
Bouwman P, Philipsen S (2002) Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol 195:27–38
Cacabelos R, Martinez-Bouza R, Carril JC, Fernandez-Novoa L, Lombardi V, Carrera I, Corzo L, McKay A (2012) Genomics and pharmacogenomics of brain disorders. Curr Pharm Biotechnol 13:674–725
Calati R, Crisafulli C, Balestri M, Serretti A, Spina E, Calabro M, Sidoti A, Albani D, Massat I, Hofer P, Amital D, Juven-Wetzler A, Kasper S, Zohar J, Souery D, Montgomery S, Mendlewicz J (2013) Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. Prog Neuropsychopharmacol Biol Psychiatry 44:271–278
Crisafulli C, Drago A, Sidoti A, Serretti A (2013) A genetic dissection of antipsychotic induced movement disorders. Curr Med Chem 20:312–330
de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66:15–27
Demyttenaere K, Albert A, Mesters P, Dewe W, De Bruyckere K, Sangeleer M (2005) What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? J Clin Psychiatry 66:859–863
Drago A, Crisafulli C, Serretti A (2011) The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample. Am J Med Genet B Neuropsychiatr Genet 156B:975–986
Esslinger C, Kirsch P, Haddad L, Mier D, Sauer C, Erk S, Schnell K, Arnold C, Witt SH, Rietschel M, Cichon S, Walter H, Meyer-Lindenberg A (2011) Cognitive state and connectivity effects of the genome-wide significant psychosis variant in ZNF804A. Neuroimage 54:2514–2523
Fabbri C, Di Girolamo G, Serretti A (2013) Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet 162B:487–520
Foltynie T, Cheeran B, Williams-Gray CH, Edwards MJ, Schneider SA, Weinberger D, Rothwell JC, Barker RA, Bhatia KP (2009) BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 80:141–144
Frederic F, Chianale C, Oliver C, Mariani J (2006) Enhanced endocrine response to novel environment stress and lack of corticosterone circadian rhythm in staggerer (Rora sg/sg) mutant mice. J Neurosci Res 83:1525–1532
Garfield LD, Dixon D, Nowotny P, Lotrich FE, Pollock BG, Kristjansson SD, Dore PM,Lenze EJ (2013) Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial. Am J Geriatr Psychiatry [Epub ahead of print]
Girgenti MJ, LoTurco JJ, Maher BJ (2012) ZNF804a regulates expression of the schizophrenia-associated genes PRSS16, COMT, PDE4B, and DRD2. PLoS One 7:e32404
Gollner H, Bouwman P, Mangold M, Karis A, Braun H, Rohner I, Del Rey A, Besedovsky HO, Meinhardt A, van den Broek M, Cutforth T, Grosveld F, Philipsen S, Suske G (2001) Complex phenotype of mice homozygous for a null mutation in the Sp4 transcription factor gene. Genes Cells 6:689–697
Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65:391–426
Gunes A, Scordo MG, Jaanson P, Dahl ML (2007) Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology 190:479–484
Hammonds MD, Shim SS (2009) Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clin Pharmacol Toxicol 105:113–119
Hauser RA, Molho E, Shale H, Pedder S, Dorflinger EE (1998) A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson’s disease patients. Tolcapone De Novo Study Group. Mov Disord 13:643–647
Heldt SA, Zimmermann K, Parker K, Gaval M, Weinshenker D, Ressler KJ (2014) BDNF deletion or TrkB impairment in amygdala inhibits both appetitive and aversive learning. J Neurosci 34:2444–2450
Hess JL, Glatt SJ (2014) How might ZNF804A variants influence risk for schizophrenia and bipolar disorder? A literature review, synthesis, and bioinformatic analysis. Am J Med Genet B Neuropsychiatr Genet 165:28–40
Ikeda E, Matsunaga N, Kakimoto K, Hamamura K, Hayashi A, Koyanagi S, Ohdo S (2013) Molecular mechanism regulating 24-hour rhythm of dopamine D3 receptor expression in mouse ventral striatum. Mol Pharmacol 83:959–967
Joels M, Pasricha N, Karst H (2013) The interplay between rapid and slow corticosteroid actions in brain. Eur J Pharmacol 719:44–52
Journiac N, Jolly S, Jarvis C, Gautheron V, Rogard M, Trembleau A, Blondeau JP, Mariani J, Vernet-der Garabedian B (2009) The nuclear receptor ROR(alpha) exerts a bi-directional regulation of IL-6 in resting and reactive astrocytes. Proc Natl Acad Sci USA 106:21365–21370
Kato M, Serretti A (2010) Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15:473–500
Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gasso P, Deulofeu R, Mane A, Catalan R, Carne X (2008) Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. Psychiatry Res 161:131–141
Leclerc E, Mansur RB, Brietzke E (2013) Determinants of adherence to treatment in bipolar disorder: a comprehensive review. J Affect Disord 149:247–252
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100
Lisowski P, Juszczak GR, Goscik J, Stankiewicz AM, Wieczorek M, Zwierzchowski L, Swiergiel AH (2013) Stress susceptibility-specific phenotype associated with different hippocampal transcriptomic responses to chronic tricyclic antidepressant treatment in mice. BMC Neurosci 14:144
Liu MT, Kuan YH, Wang J, Hen R, Gershon MD (2009) 5-HT4 receptor-mediated neuroprotection and neurogenesis in the enteric nervous system of adult mice. J Neurosci 29:9683–9699
Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J (1995) Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34:4202–4210
McCarthy MJ, Wei H, Marnoy Z, Darvish RM, McPhie DL, Cohen BM, Welsh DK (2013) Genetic and clinical factors predict lithium’s effects on PER2 gene expression rhythms in cells from bipolar disorder patients. Transl Psychiatry 3:e318
McClay JL, Adkins DE, Aberg K, Bukszar J, Khachane AN, Keefe RS, Perkins DO, McEvoy JP, Stroup TS, Vann RE, Beardsley PM, Lieberman JA, Sullivan PF, van den Oord EJ (2011) Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology 36:616–626
Muller DJ, Chowdhury NI, Zai CC (2013) The pharmacogenetics of antipsychotic-induced adverse events. Curr Opin Psychiatry 26:144–150
Pinacho R, Villalmanzo N, Lalonde J, Haro JM, Meana JJ, Gill G, Ramos B (2011) The transcription factor SP4 is reduced in postmortem cerebellum of bipolar disorder subjects: control by depolarization and lithium. Bipolar Disord 13:474–485
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559–575
Racaniello M, Cardinale A, Mollinari C, D’Antuono M, De Chiara G, Tancredi V, Merlo D (2010) Phosphorylation changes of CaMKII, ERK1/2, PKB/Akt kinases and CREB activation during early long-term potentiation at Schaffer collateral-CA1 mouse hippocampal synapses. Neurochem Res 35:239–246
Ray MT, Shannon Weickert C, Webster MJ (2014) Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders. Transl Psychiatry 4:e389
Sachs GS, Guille C, McMurrich SL (2002) A clinical monitoring form for mood disorders. Bipolar Disord 4:323–327
Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, Calabrese J, Kupfer D, Rosenbaum JF (2003) Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 53:1028–1042
Saiz PA, Susce MT, Clark DA, Kerwin RW, Molero P, Arranz MJ, de Leon J (2008) An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects. Hum Psychopharmacol 23:107–114
Sato C, Kitajima K (2013) Impact of structural aberrancy of polysialic acid and its synthetic enzyme ST8SIA2 in schizophrenia. Front Cell Neurosci 7:61
Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, Dorevitch A, Yakir A, Greenberg D, Lerner A, Lerer B (2001) Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 6:225–229
Serretti A, Chiesa A, Calati R, Fabbri C, Sentissi O, De Ronchi D, Mendlewicz J, Souery D (2013) Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. J Psychopharmacol 27:616–628
Shaw AD, Tiwari Y, Kaplan W, Heath A, Mitchell PB, Schofield PR, Fullerton JM (2014) Characterisation of genetic variation in ST8SIA2 and its interaction region in NCAM1 in patients with bipolar disorder. PLoS One 9:e92556
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59((Suppl 20)):22–33 (quiz 34–57)
Sikander A, Rana SV, Prasad KK (2009) Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin Chim Acta 403:47–55
Simons CJ, van Winkel R, Group (2013) Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition. Schizophr Bull 39:848–856
Souery D, Zaninotto L, Calati R, Linotte S, Sentissi O, Amital D, Moser U, Kasper S, Zohar J, Mendlewicz J, Serretti A (2011) Phenomenology of psychotic mood disorders: lifetime and major depressive episode features. J Affect Disord 135:241–250
Souery D, Zaninotto L, Calati R, Linotte S, Mendlewicz J, Sentissi O, Serretti A (2012) Depression across mood disorders: review and analysis in a clinical sample. Compr Psychiatry 53:24–38
Srivastava V, Varma PG, Prasad S, Semwal P, Nimgaonkar VL, Lerer B, Deshpande SN, Bk T (2006) Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 16:111–117
Staeker J, Leucht S, Laika B, Steimer W (2014) Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients. Genet Test Mol Biomark 18:20–31
Staudt MD, de Oliveira CV, Lehman MN, McKenna KE, Coolen LM (2010) Activation of MAP kinase in lumbar spinothalamic cells is required for ejaculation. J Sex Med 7:2445–2457
Stojkov NJ, Janjic MM, Baburski AZ, Mihajlovic AI, Drljaca DM, Sokanovic SJ, Bjelic MM, Kostic TS, Andric SA (2013) Sustained in vivo blockade of alpha(1)-adrenergic receptors prevented some of stress-triggered effects on steroidogenic machinery in Leydig cells. Am J Physiol Endocrinol Metab 305:E194–E204
Utge SJ, Soronen P, Loukola A, Kronholm E, Ollila HM, Pirkola S, Porkka-Heiskanen T, Partonen T, Paunio T (2010) Systematic analysis of circadian genes in a population-based sample reveals association of TIMELESS with depression and sleep disturbance. PLoS One 5:e9259
Van Den Bossche MJ, Docx L, Morrens M, Cammaerts S, Strazisar M, Bervoets C, Smolders S, Depreeuw V, Lenaerts AS, De Rijk P, Del-Favero J, Sabbe BG (2012) Less cognitive and neurological deficits in schizophrenia patients carrying risk variant in ZNF804A. Neuropsychobiology 66:158–166
van der Heijden KB, de Sonneville LM, Swaab H (2013) Association of eveningness with problem behavior in children: a mediating role of impaired sleep. Chronobiol Int 30:919–929
Van Rheenen TE, Rossell SL (2013) Genetic and neurocognitive foundations of emotion abnormalities in bipolar disorder. Cogn Neuropsychiatry 18:168–207
Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382:1575–1586
Wilffert B, Al Hadithy AF, Sing VJ, Matroos G, Hoek HW, van Os J, Bruggeman R, Brouwers JR, van Harten PN (2009) The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: curacao extrapyramidal syndromes study IX. J Psychopharmacol 23:652–659
Yamashita S, Tai P, Charron J, Ko C, Ascoli M (2011) The Leydig cell MEK/ERK pathway is critical for maintaining a functional population of adult Leydig cells and for fertility. Mol Endocrinol 25:1211–1222
Yuan P, Zhou R, Wang Y, Li X, Li J, Chen G, Guitart X, Manji HK (2010) Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. J Affect Disord 124:164–169
Zai CC, Tiwari AK, Muller DJ, De Luca V, Shinkai T, Shaikh S, Ni X, Sibony D, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL (2010) The catechol-O-methyl-transferase gene in tardive dyskinesia. World J Biol Psychiatry 11:803–812
Zhou X, Long JM, Geyer MA, Masliah E, Kelsoe JR, Wynshaw-Boris A, Chien KR (2005) Reduced expression of the Sp4 gene in mice causes deficits in sensorimotor gating and memory associated with hippocampal vacuolization. Mol Psychiatry 10:393–406
Zivkovic M, Mihaljevic-Peles A, Bozina N, Sagud M, Nikolac-Perkovic M, Vuksan-Cusa B, Muck-Seler D (2013) The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. J Clin Psychopharmacol 33:593–599
Acknowledgments
The STEP-BD project was funded in whole or in part with Federal Funds from the National Institute of Mental Health (NIMH), under contract N01MH8001. Collection of DNA from consenting participants in STEP-BD was supported by N01MH80001 (Gary S. Sachs, M.D., principal investigator). Sample collection funding was supported by NIH grants (MH067288, Pamela Sklar; MH063445, Jordan W. Smoller; MH63420, Vish Nimgaonkar). Genotyping was funded by grants from NIH (MH067288 Pamela Sklar, PI), Johnson & Johnson Pharmaceutical Research and Development, Sylvan C. Herman Foundation, Stanley Medical Research Foundation, and Merck Genome Research Institute (Edward Scolnick, PI). We thank Manuel Mayhaus (University of Saarlandes, Germany) for technical assistance with Sequenom MassArray platform.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Fabbri, C., Souery, D., Calati, R. et al. Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. J Neural Transm 122, 43–58 (2015). https://doi.org/10.1007/s00702-014-1290-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-014-1290-3